Revenue from operations rose 29.87% YoY to Rs 965 crore in Q4 FY26, while increasing 8.67% QoQ from Rs 888 crore.

Profit before tax stood at Rs 189 crore in Q4 FY26, rebounding from a loss of Rs 22 crore in the year-ago period. PBT surged 182.09% QoQ from Rs 67 crore in Q3 FY26.

EBITDA stood at Rs 196 crore in Q4 FY26, up 148.10% YoY and 13.29% QoQ, while margin expanded sharply to 20.3% from 10.7% in the year-ago period.

On the cost side, cost of materials consumed increased 11.32% YoY to Rs 177 crore, while employee expenses rose 12.65% YoY to Rs 187 crore and other expenses were up 10.92% YoY at Rs 264 crore.

Exceptional items for FY26 stood at Rs 85 crore, including one-time charges related to restructuring, regulatory compliance, US entity liquidation and labour code impact. During the quarter, the company recorded a net charge of Rs 12.70 crore related to settlement with a bankruptcy trustee, while a Rs 35.35 crore gain from settlement with Dr. Reddy’s was recognised.

Operationally, growth was led by strong traction across key regions, with the India business rising 18% YoY to Rs 112 crore and the UK business growing 20% YoY to Rs 349 crore. Emerging markets delivered robust expansion of 124% YoY to Rs 320 crore, while the Ireland business increased 12% YoY to Rs 52 crore.

For the full year FY26, the company reported a net profit of Rs 199 crore compared to a loss of Rs 57 crore in FY25. Revenue rose 11.21% to Rs 3,373 crore from Rs 3,033 crore in the previous year. EBITDA for FY26 stood at Rs 630 crore, up 50.72% YoY, with margin improving to 18.7% from 13.8% in FY25.

Wockhardt is a research based global pharmaceutical and biotech company. It employs around ~3200 people and 27 nationalities with presence in UK, Ireland, Switzerland, France, Mexico, Russia and many other countries.